NHL Clinical Trial
Official title:
A Phase II Study Evaluating the Feasibility and Clinical Efficacy of Atezolizumab Consolidation Treatment in High Risk Diffuse Large B-cell Lymphoma
The prognosis of Diffuse Large B cell Lymphoma (DLBCL) patients with an early relapse is dismal. Atezolizumab has shown promising activity in relapsed DLBCL patients. Toxicity data on atezolizumab are available for > 6000 patients and is manageable. The assumption of this study is that atezolizumab consolidation will result in higher disease free survival by eradicating minimal residual disease In melanoma and lung cancer consolidation immunotherapy after chemoradiotherapy has shown an increase in survival.
In high risk diffuse large B-cell lymphoma (DLBCL), International Prognostic Index (IPI)-score ≥ 3 21% of patients will relapse within 2-years after completion of R-CHOP induction treatment despite achieving a complete remission. Patient relapsing within a year after R-CHOP treatment have a very poor prognosis, even after second line chemotherapy, with only 15% of patients achieving a long remission. Therefore, additional therapy in first line treatment is required for these patients. The immune checkpoint inhibitor atezolizumab is a monoclonal antibody directed against the program death ligand 1 (PDL1). The PD1 and PDL1 inhibitors have shown excellent results in relapsed Hodgkin lymphoma and promising results in relapsed B-cell non Hodgkin lymphoma. Given the acceptable toxicity profile of atezolizumab, this study examines the efficacy and toxicity of atezolizumab as consolidation treatment after R-CHOP induction in DLBCL patients at high risk of relapse. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00333190 -
CD8+ T Cell Depletion for GVHD Prophylaxis After Peripheral Blood Stem Cell Transplantation
|
N/A | |
| Recruiting |
NCT03535753 -
Safety and Efficacy Evaluation of Decitabine With R-GDP
|
Phase 1 | |
| Completed |
NCT00513175 -
Non-Myeloablative Allogeneic Stem Cell Transplantation With Matched Unrelated Donors for Treatment of Hematologic Malignancies, Renal Cell Carcinoma, and Aplastic Anemia
|
N/A | |
| Completed |
NCT00342121 -
Influence of Corn Farming on the Immune System
|
||
| Active, not recruiting |
NCT01101581 -
Study of Veltuzumab and 90Y-Epratuzumab in Relapsed/Refractory, Aggressive NHL
|
Phase 1/Phase 2 | |
| Not yet recruiting |
NCT03789240 -
Response-Adapted Therapy With Copanlisib and Rituximab in Untreated Follicular Lymphoma
|
Phase 2 | |
| Recruiting |
NCT02702492 -
PAK4 and NAMPT in Patients With Solid Malignancies or NHL (PANAMA)
|
Phase 1 | |
| Recruiting |
NCT03527147 -
Platform Study for the Treatment of Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma (PRISM Study)
|
Phase 1 | |
| Terminated |
NCT00814983 -
Myeloablative Allogeneic Stem Cell Transplantation Using a Naive T-Cell Depleted Peripheral Blood Stem Cell Graft
|
Phase 1/Phase 2 | |
| Completed |
NCT00891592 -
Umbilical Cord Blood Transplant for Hematological Malignancies
|
Phase 1 | |
| Completed |
NCT00546793 -
Ph I/II Study of Subcutaneously Administered Veltuzumab (hA20) in NHL and CLL
|
Phase 1/Phase 2 | |
| Not yet recruiting |
NCT02847949 -
A Study of IGN002 for Refractory NHL
|
Phase 2 | |
| Recruiting |
NCT03739502 -
A Randomized Phase II Study of Hyperbaric Oxygen in Improving Engraftment in Umbilical Cord Blood Stem Cell Transplant
|
Phase 2 | |
| Recruiting |
NCT02315612 -
Anti-CD22 Chimeric Receptor T Cells in Pediatric and Young Adults With Recurrent or Refractory CD22-expressing B Cell Malignancies
|
Phase 1 | |
| Recruiting |
NCT00515892 -
Safety Study of CAT-8015 Immunoxin in Patients With NHL With Advance Disease
|
Phase 1 | |
| Completed |
NCT00421395 -
Safety Study of NHL With 90Y-hLL2 IgG
|
Phase 1/Phase 2 | |
| Recruiting |
NCT03465540 -
Safety, Tolerability, Pharmacokinetics and Efficacy of AMG 397 in Subjects With Multiple Myeloma, NHL, and AML
|
Phase 1 | |
| Terminated |
NCT02110563 -
Phase I, Multicenter, Dose Escalation Study of DCR-MYC in Patients With Solid Tumors, Multiple Myeloma, or Lymphoma
|
Phase 1 | |
| Terminated |
NCT00471367 -
Phase I, Open-label, Dose-escalation, Safety and PK Study of AZD4877
|
Phase 1 |
